Table 2. Main characteristics of the eligible studies for prognostic meta-analysis.
| Author | Country/year | MiR-525 type | Expression status | Cancer type | Specimen | Test method | Patients | Follow-up period (months) | Survival result | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Hui-Hua Tang | China/2023 | miR-525-5p | Down-regulated | BC | Tissue | RT-qPCR | 180 | 60 | RFS, OS | 0.13 (0.02–0.78) |
| Jin Wang | China/2021 | miR-525-5p | Down-regulated | THYM | Tissue | RT-qPCR | 70 | 60 | OS | 0.31 (0.05–2.09) |
| Ting Zhao | China/2020 | miR-525-5p | Down-regulated | DLBCL | Tissue | RT-qPCR | 74 | 180 | OS | 0.14 (0.04–0.49) |
HR, hazard ratio; CI, confidence interval; BC, breast cancer; RT-qPCR, quantitative real-time polymerase chain reaction; RFS, recurrence free survival; OS, overall survival; THYM, thymoma and thymic carcinoma; DLBCL, diffuse large B-cell lymphoma.